Neurovation Labs is a biotech company focused CNS disorders, starting first with Post-traumatic Stress Disorder (PTSD).
Neurovation Labs grew out of the research performed by Drs. Fanselow and Perusini that sought to understand the cause of PTSD on a physiological level. They discovered that PTSD is manifested through enduring protein increases (glutamate receptor subunit GluA1) in the fear learning center of the brain, the amygdala. This protein increase provides the first putative biomarker of PTSD and provides the backbone for both Neurovation Labs’ PTSD treatment and companion diagnostic for PTSD, as well as for other CNS disorders implicating the glutamatergic system.